FDA Approves Verastem’s Ovarian Cancer Therapy for Some Adult Patients

It marks the first and only approval for a drug to treat adults with low-grade serous ovarian cancer.
FDA Approves Verastem’s Ovarian Cancer Therapy for Some Adult Patients
The U.S. Food and Drug Administration building in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times
Katabella Roberts
Updated:
0:00

The Food and Drug Administration (FDA) has granted accelerated approval to biopharmaceutical company Verastem Oncology’s combination therapy for adults who have received prior treatment for a rare type of ovarian cancer, the regulator announced on Thursday.

The FDA approved Avmapki Fakzynja co-pack (avutometinib capsules; defactinib tablets) for patients with recurrent Kirsten rat sarcoma viral oncogene homolog (KRAS) mutated low-grade serous ovarian cancer (LGSOC) who received prior systemic therapy.
Katabella Roberts
Katabella Roberts
Author
Katabella Roberts is a news writer for The Epoch Times, focusing primarily on the United States, world, and business news.